Clinical trials: Myeloid Tumor
Acute Myeloid Leukemia, Leukemia, Acute Myeloid
Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
The primary objective of this study is to demonstrate the efficacy of Iomab-B, in conjunction with a Reduced Intensity Conditioning (RIC) regimen and protocol-specified allogeneic hematopoietic stem cell transplant (HCT), versus…
- Conditions
- Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute, Leukemia, Myeloid, Acute
- Trial name
- SIERRA (NCT02665065)
- Testing
- Iomab-B, Conventional Care, HCT
- Where
- 24 sites in United States, Canada
- Volunteers
- 153 people
- Sponsor
- Actinium Pharmaceuticals
Hyperglycemia, Leukemia
Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia
RATIONALE: Controlling blood sugar levels may be effective in preventing infections in patients receiving chemotherapy for acute myeloid leukemia or acute lymphoblastic leukemia.
- Trial name
- NCT00943709
- Testing
- insulin glargine recombinant, therapeutic insulin
- Where
- United States
- Sponsor
- University of Medicine and Dentistry of New Jersey
Acute Myeloid Leukemia
Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia
To evaluate the tolerability and pharmacokinetics of SGI-110 when administered subcutaneously to Japanese patients with acute myeloid leukemia (AML).
- Trial name
- NCT02293993
- Testing
- SGI-110
- Where
- 3 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia
A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies
This study consists of two phases: the first portion of the study is a Phase 1 dose escalation study to determine the maximum tolerated dose and the dose limiting toxicities of SB1518 when given as a single agent orally once…
- Conditions
- Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00719836
- Testing
- SB1518
- Where
- 3 sites in United States
- Volunteers
- 76 people
- Sponsor
- S*BIO
Recurrent Adult Acute Myeloid Leukemia, Myelodysplastic Syndrome
A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML
The goal of this clinical trial] is to evaluate mitoxantrone hydrochloride liposomes, subcutaneous injection of cytarabine and G-CSF combined with Venetoclax (CMG+Ven) in adult secondary acute myeloid leukemia and myelodysplastic…
- Conditions
- Recurrent Adult Acute Myeloid Leukemia, Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia
- Trial name
- NCT06329999
- Testing
- CMGV
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Ruijin Hospital
Acute Myeloid Leukemia
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
This phase I trial identifies the best dose and clinical benefit of giving pemigatinib following standard induction chemotherapy in patients with newly diagnosed acute myeloid leukemia.
- Trial name
- NCT04659616
- Testing
- Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- OHSU Knight Cancer Institute
TNBC - Triple-Negative Breast Cancer, Breast Cancer
ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation
Open label, single-arm, prospective therapeutic trial. Pembrolizumab (MK-3475), 200 mg IV Q3W starting at C1D1/Week 1 for up to 2 years, until disease progression, or treatment intolerance.
- Trial name
- NCT07015853
- Testing
- Pembrolizumab, Radiotherapy, Axatilimab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Stephen Shiao
Acute Myeloid Leukemia
Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96
This is an retrospective and prospective observational multinstitutional study to evaluate the impact on outcome of the combination of HMA plus venetoclax in AML patients unfit for intensive chemotherapy in a "real-life"…
- Trial name
- NCT04589728
- Testing
- Venetoclax plus HMA
- Where
- 23 sites in Italy
- Volunteers
- 202 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Myeloid Leukemia, Adult
Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia
Pegylated arginine deiminase (ADI-PEG 20) will be combined with venetoclax and azacitidine for treatment of subjects with previously treated or untreated with high risk factor acute myeloid leukemia (AML).
- Trial name
- NCT05001828
- Testing
- ADI-PEG 20
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Polaris Group
Acute Myeloid Leukemia (AML)
PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
RATIONALE: PKC412 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. It may also increase the effectiveness of daunorubicin and cytarabine by making cancer cells more sensitive to the drugs.
- Trial name
- NCT00093600
- Testing
- cytarabine, daunorubicin hydrochloride, midostaurin
- Where
- 6 sites in United States, Germany
- Volunteers
- 69 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myeloid Leukemia
Follow-up of Ph+ Chronic Myleoid Leukemia Patients in Complete Cytogenetic Response With Interferon Based Therapy
Objectives This is an observational study aimed at updating the overall survival (OS), the progression free survival (PFS) to accelerated-blastic (AB) phase and the complete cytogenetic response (CCgR) duration of the CML…
- Trial name
- NCT01490853
- Testing
- Interpheron alpha
- Where
- Italy
- Volunteers
- 116 people
- Sponsor
- Università degli Studi di Brescia
Leukemia, Promyelocytic, Acute
APL93: Timing of CxT and Role of Maintenance
Objectives of the trial were to assess the optimal timing of chemotherapy with or after ATRA and the role of maintenance therapy.
- Trial name
- NCT00599937
- Testing
- ATRA, ATRA and or Chemo as maintenance
- Volunteers
- 576 people
- Sponsor
- Groupe d'etude et de travail sur les leucemies aigues promyelocytaires
Acute Lymphoblastic Leukemia, ALL
Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD
Patients are being asked to participate in this study because treatment for their disease requires a stem cell transplant (SCT).
- Conditions
- Acute Lymphoblastic Leukemia, ALL, Acute Myelogenous Leukemia, AML
- Trial name
- IL2 for GVHD (NCT00539695)
- Testing
- IL-2
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Baylor College of Medicine
Leukemia
Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)
The purpose of the study is to determine the safety and tolerability of the combination of BMS-833923 plus dasatinib in patients with chronic myeloid leukemia.
- Trial name
- NCT01218477
- Testing
- Dasatinib, BMS-833923
- Where
- 12 sites in United States, Canada and 5 more
- Volunteers
- 33 people
- Sponsor
- Bristol-Myers Squibb
Acute Myeloid Leukemia
CAV Regimen for R/R AML
This study aims to investigate the efficacy and safety of cladribine, combined with low-dose cytarabine and venetoclax (CAV regimen) for relapsed/refractory acute myeloid leukemia (R/R AML).
- Trial name
- NCT05657639
- Testing
- CAV Regimen, MEC Regimen
- Where
- China
- Volunteers
- 68 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Relapsed/Refractory T-cell Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia
CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia
CD70 is a promising target for immunotherapy because it is overexpressed in T-cell lymphoma (TCL) and acute myeloid leukemia (AML) tumor cells but is found in deficient levels in normal tissues and hematopoietic stem cells.
- Trial name
- NCT06696846
- Testing
- CD70 CAR-NK
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia-1
Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies
The primary purpose of this multi-centre, randomized, placebo-controlled, double-blind phase II study is to investigate if oral vitamin C may change the biology of low-risk myeloid malignancies; i.e., clonal cytopenia of…
- Conditions
- Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia-1, Cytopenia
- Trial name
- EVITA (NCT03682029)
- Testing
- Vitamin C (ascorbic acid)
- Where
- 5 sites in United States, Denmark
- Volunteers
- 109 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Acute Myeloid Leukemia
FLT3 Clonal Evolution in Patients With Acute Myeloid Leukemia
This retrospective cohort study aims to describe the current FLT3 testing landscape in Taiwan. It includes two patient groups: non-M3 primary AML patients with relapsed/refractory disease (R/R cohort) and newly diagnosed non-M3…
- Trial name
- NCT06463639
- Where
- Taiwan
- Volunteers
- 1,213 people
- Sponsor
- National Taiwan University Hospital
Leukemia
"AIDA" Protocol (LAP 0493)
The main purposes of the AIDA protocol are to test the role of intermittent maintenance therapy with ATRA, standard maintenance chemotherapy with methotrexate and 6-mercaptopurine of both in PCR negative patients at the end of…
- Trial name
- NCT01064557
- Testing
- all-trans retinoic acid (ATRA)
- Where
- 80 sites in Belgium, Germany and 3 more
- Volunteers
- 1,068 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Reduced intensity conditioning (RIC) has emerged and been increasingly adopted as a modality to allow preparative conditioning pre transplant to be tolerated by older adults or those patients that are otherwise unfit for…
- Conditions
- Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies, Acute Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT05088356
- Testing
- Purified regulatory T-cells (Treg) plus CD34+ HSPC, Fludarabine, Melphalan
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Stanford University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.